The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved AstraZeneca's Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF ...
AstraZeneca PLC (NASDAQ:AZN), a pharmaceutical and biotech firm based in Cambridge, UK, reported positive results from its Phase 3b Batura trial. The study found that Airsupra, its dual-action asthma ...
A new inhaler that treats chronic obstructive pulmonary disease (COPD) and also helps reduce environmental harm has been approved for use in the UK. This inhaler is already available in India.
Full results published in the New England Journal of Medicine and presented at ATS 2025 International Conference BATURA builds upon the previous Phase III MANDALA and DENALI trials and in totality, ...
July 25 (Reuters) - A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's (AZN.L), opens new tab inhaler for the treatment of a chronic lung ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma. 1 The BATURA Phase IIIb trial, ...
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) announced a major update to the U.S. prescribing information for AIRSUPRA, following new clinical evidence from the BATURA study. This Phase IIIb ...
AstraZeneca has partnered with New Zealand-based Adherium Limited, which offers a mobile-enabled inhaler, to incorporate digital health offerings into AstraZeneca’s patient support programs for people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback